< Back to previous page
Researcher
Steven Goossens
- Keywords:In vitro models, cell biology, in vivo animal models, mouse model, translational research, leukemia, Metastasis
- Disciplines:Hematology, Cancer biology, Cancer therapy
Affiliations
- Department of Diagnostic Sciences (Department)
Member
From1 Oct 2019 → Today - Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → 30 Sep 2019 - Department of Pediatrics and medical genetics (Department)
Member
From1 Oct 2016 → 30 Sep 2018 - Department of Biomedical molecular biology (Department)
Member
From1 Feb 2000 → 30 Sep 2019
Infrastructure
1 - 1 of 1
- Patient Derived Xenograft Platform Ghent (Consortium coordinator)
Projects
1 - 10 of 34
- The role of SOX11 in innate B-cell development and Mantle Cell LymphomaFrom1 Nov 2025 → TodayFunding: FWO fellowships
- Drug response profiling of adult T-cell acute lymphoblastic leukemia to optimize salvage therapies for relapsed/refractory patientsFrom1 Nov 2025 → TodayFunding: FWO Strategic Basic Research Grant
- Unraveling the role of Ikaros in pre-leukemic T-cell acute lymphoblastic leukemiaFrom1 Oct 2025 → TodayFunding: FWO junior postdoctoral fellowship
- Targeting the amino acid stress response pathway in aggressive cancer subtypesFrom1 Jan 2025 → TodayFunding: BOF - projects
- Towards clinical testing of improved, less toxic and less immunogenic, L-asparaginase formulations for the treatment of ovarian cancerFrom1 Nov 2024 → TodayFunding: FWO Strategic Basic Research Grant
- The role of PSIP1 and Menin in T-cell acute lymphoblastic leukemia (T-ALL)From1 Nov 2024 → 30 Apr 2025Funding: BOF - doctoral mandates
- Plastistatic ZEB1 mediated EMT modulators to block colon and cancer progressionFrom1 Sep 2024 → TodayFunding: IOF - technology validation in lab
- Cofunding Core Facility - Patient-derived xenograft modelsFrom1 Feb 2024 → TodayFunding: BOF - research organisations
- CRISPR-cas9 targeting in T-ALLFrom1 Jan 2024 → 31 Dec 2024Funding: BOF - projects
- Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trialFrom1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
Publications
1 - 10 of 87
- Peptide hydrogels as slow-release formulations of protein therapeutics : case study of asparaginase-loaded hydrogels(2025)Published in: BIOMATERIALS SCIENCEISSN: 2047-4849Issue: 15Volume: 13Pages: 4139 - 4152
- Modeling of glucocorticoid resistance in multiple myeloma reveals mechanisms and markers of glucocorticoid resistance(2025)Published in: BIOMEDICINE & PHARMACOTHERAPYISSN: 1950-6007Volume: 192
- A human-like glutaminase-free asparaginase is highly efficacious in ASNS-low leukemia and solid cancer mouse xenograft models(2025)Published in: CANCER LETTERSISSN: 1872-7980Volume: 611
- Ikaros loss enhances pre-leukemic thymocyte self-renewal and drives T-all in mice(2024)Volume: 137Pages: 87 - 87
- Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia(2024)Published in: BLOOD ADVANCESISSN: 2473-9537Issue: 11Volume: 8Pages: 2646 - 2649
- A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia(2024)Published in: SCIENCE ADVANCESISSN: 2375-2548Issue: 44Volume: 10
- ZEB2 drives intra-tumor heterogeneity and skin squamous cell carcinoma formation with distinct EMP transition states(2024)Published in: ISCIENCEISSN: 2589-0042Issue: 11Volume: 27
- Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids(2024)Published in: ONCOGENEISSN: 1476-5594Issue: 3Volume: 43Pages: 155 - 170
- In vivo stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia(2023)Published in: HAEMATOLOGICAISSN: 1592-8721Issue: 2Volume: 108Pages: 409 - 419
- A role for IKZF1 in pre-leukemic T-all?(2023)Volume: 124Pages: S152 - S152